Santen Pharmaceutical Co (SNPHY)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

Santen Pharmaceutical Co (SNPHY) is up 8.9% since the beginning of the year. At $11 per share, SNPHY is trading 11.5% below its 52-week high of $13. Investors who bought $1,000 worth of SNPHY shares 5 years ago would now be looking at an investment worth $868.

Santen Pharmaceutical Co (SNPHY) has returned 8.93% so far this year and -0.00% over the past 12 months. Over the last ten years, SNPHY has returned -2.70% per year, falling short of the S&P 500 Index benchmark, which averaged 13.75% annually.

Based on dividend-adjusted daily data since Aug 31, 2011, SNPHY's average daily return is +0.02%, while the average monthly return is +0.21%. At this rate, an investment would double in approximately 27.5 years.

Historically, 56% of months were positive and 44% were negative. The best month was May 2014 with a return of +22.2%, while the worst month was Apr 2015 at -64.0%. The longest winning streak lasted 5 consecutive months, and the longest losing streak was 4 months.

On a daily basis, SNPHY closed higher 46% of trading days. The best single day was Dec 20, 2011 with a return of +25.3%, while the worst single day was Apr 2, 2015 at -58.5%.

Santen Pharmaceutical Co has an annualized alpha of -1.13%, beta of 0.46, and R2 of 0.04 versus S&P 500 Index. Calculated based on daily prices since September 01, 2011.

• This stock participated in 69.88% of S&P 500 Index downside but only 17.51% of its upside - more exposed to losses than it benefited from rallies.
• Beta of 0.46 may look defensive, but with R2 of 0.04 this stock is largely uncorrelated with S&P 500 Index - low beta reflects independence, not downside protection. See the Volatility section for a true picture of this stock's risk.
• R2 of 0.04 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

SNPHY ranks 39 for risk / return — below 39% of stocks on our site. The returns aren't fully compensating for the risk involved. This isn't necessarily a dealbreaker, but factor it into your decision — especially if you're risk-averse.

The table below present risk-adjusted performance metrics for Santen Pharmaceutical Co (SNPHY) and compare them to S&P 500 Index.

Santen Pharmaceutical Co provided a 0.00% dividend yield over the last twelve months, with an annual payout of $0.00 per share.

The table displays the monthly dividend distributions for Santen Pharmaceutical Co. The dividends shown in the table have been adjusted to account for any splits that may have occurred.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Santen Pharmaceutical Co. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Santen Pharmaceutical Co was 82.47%, occurring on Nov 8, 2022. The portfolio has not yet recovered.

The current Santen Pharmaceutical Co drawdown is 68.71%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Santen Pharmaceutical Co over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Santen Pharmaceutical Co is priced in the market compared to other companies in the Drug Manufacturers - General industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.